SIXTH MEETING OF THE WORKING GROUP ON MDR-TB OF THE STOP TB PARTNERSHIP

20 - 22 SEPTEMBER 2007, TBILISI, GEORGIA.

http://stoptb.events.ge
Introduction

Emergence of XDR-TB in 2006 has highlighted more than ever the need for strengthening basic TB control and for adequate prevention and control of drug resistant TB. In 2007, major activities are being undertaken at global, regional and country levels to further strengthen basic TB control programmes and provide treatment and care to patients with MDR-TB and XDR-TB, as described in the “Global MDR-TB and XDR-TB Response Plan 2007-2008” (http://www.stoptb.org/resource_center/assets/documents).

This 6th Working Group (WG) meeting in 2007 will be crucial to build and sustain the political momentum for MDR-TB and XDR-TB control and strengthen and advance the activities of the Working Group and its subgroups.

Experience in the management of MDR-TB, fostered by the work of the Green Light Committee (GLC) initiative, continues to grow as WHO and the Stop TB Partnership galvanizes processes with countries and technical partners. Nevertheless, improvements are needed to strengthen communication and information sharing between country projects, as recognized during the 5th meeting of the Working Group on MDR-TB held in Atlanta, US, 10 May, 2006. This meeting of the Working Group will bring together projects approved by the GLC to share not only their best practices, but also the challenges being faced while mainstreaming MDR-TB management into routine TB control, in line with the new Stop TB strategy. The lessons learned in this process will feed the debate on the strategic steps to be taken to accelerate the scale-up of MDR-TB management, according to Global Plan to Stop TB 2006-2015.

Objectives

1. Create further awareness around the global emergency of MDR-TB and XDR-TB in order to plan a much accelerated response by all individuals and agencies of the WG
2. Assess the lessons learned by National TB Control Programmes and GLC approved projects in the management of MDR-TB to inform policy formulations
3. Review progress achieved by the subgroups of the WG on MDR-TB and other relevant subgroups
4. Examine the progress in scaling-up MDR-TB control according to the Global Plan to Stop TB, 2006-2015 and make decisions about ways to accelerate
5. Analyse challenges to scale up MDR-TB management and accelerate mobilization of resources by the StopTB community
Welcoming remarks
Thelma Tupasi, Chair of the Working Group (WG) on MDR-TB

Key note address by Ms. Sandra Elisabeth Roelofs,
First Lady of Georgia, Stop TB Ambassador.

Opening address by H E David Tkeshelashvili
Minister of Labour, Health and Social Affairs of Georgia

From dreams to reality check on MDR-TB management scale up
Dr Mario Raviglione, Director of the Stop TB Department, WHO Geneva

Dr Michael Kimerling, member of the Core Group of the WG on MDR-TB

The challenge of mobilizing the resources to scale up MDR-TB management
Dr Paul Nunn, Coordinator, TB/HIV and Drug Resistance, WHO

“Rise-up for Scale-up, from the Bottom-up!”: Community driven civil society mobilization for MDR-TB (Now!)
Case Gordon, World Care Council, and Simon Lobo, MISBAH

Presentation of the agenda of the meeting
Dr Thelma Tupasi, Chair of the Working Group on MDR-TB

COFFEE BREAK
### Session 1
Managing MDR-TB: experiences at country level

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Type</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 11:20</td>
<td>SALKHINO</td>
<td>PLENARY</td>
<td>Lessons learned in the scale-up of MDR-TB management</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Amy Bloom (USAID)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plenary presentations: Archil Salakaia (Georgia) and Lynne Vianzon (Philippines)</td>
</tr>
<tr>
<td>11:20 - 11:50</td>
<td>SALKHINO</td>
<td>PLENARY</td>
<td>Lessons learned on management of second-line anti-TB drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Amy Bloom (USAID)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plenary presentations: Jaime Bayona (Peru) and Vladislav Erokhin (Russia)</td>
</tr>
<tr>
<td>11:50 - 12:50</td>
<td>SALKHINO</td>
<td>SIMULTANEOUS BREAK-OUT SESSIONS</td>
<td>a) Scaling-up MDR-TB management</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Jose Caminero (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Facilitator: Salmaan Keshavjee (US)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rapporteur: Irina Sahakyan (WHO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>b) Management of second-line anti-TB drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Paul Zintl (US)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Facilitator: Joel Keravec (Brasil)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rapporteur: Barbara Milani (Global Drug Facility)</td>
</tr>
<tr>
<td>12:50 - 13:50</td>
<td></td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:20</td>
<td>SALKHINO</td>
<td>PLENARY</td>
<td>Building laboratory capacity to deal with MDR-TB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Zhao Yanlin (China)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plenary presentations: Moselinyane Letsie (Lesotho) and R O’Brien (FIND); Francis Varaine ('Doctors without Borders' / Medecines sans Frontiers)</td>
</tr>
<tr>
<td>14:20 - 14:50</td>
<td>SALKHINO</td>
<td>PLENARY</td>
<td>TB Infection Control:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Zhao Yanlin (China)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Martin Yagui (Peru)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bess Miller (US)</td>
</tr>
</tbody>
</table>
Friday, 21 September

9:00 - 9:30  SALKHINO  PLENARY
Scaling-up patient and community participation in the Response to MDR/XDR.
Chair: Khaled Abu Ramman (Jordan)
Plenary presentations: Maxime Lunga (DR Congo) and Natalie Tarenec; Mamel Quelapio (Philippines)

9:30 - 10:00  SALKHINO  PLENARY
Recording and Reporting in MDR-TB
Chair: Khaled Abu Ramman (Jordan)
Plenary presentations: Einar Heldal (LHL); Maria Rodriguez (Dominican Republic)

10:00 - 10:20  SALKHINO  COFFEE BREAK

10:20 - 11:20  SALKHINO  BREAK-OUT SESSIONS
a) Scaling-up patient and community participation in the Response to MDR/XDR.
Chair: Case Gordon (France)
Facilitators: Natalie Tarenec (Ukraine)
Rapporteur: Mick Matthews (Global Fund)

11:20 - 12:00  SALKHINO  PLENARY
TB infection control: no longer neglected
Chair: Margaret Dalcolmo (Brasil)
What’s new in airborne infection control? Paul Jensen (US CDC)
The WHO guidelines: what’s the way forward? Bess Miller (US CDC)

12:00 - 13:00  SALKHINO  COFFEE BREAK

13:00 - 14:00  LILE  SIMULTANEOUS BREAK-OUT SESSIONS
a) Laboratory and drug resistant TB
Chair: John Ridderhof (US CDC)
Facilitator: Kitty Lambregts (KNCV)
Rapporteur: Malgosia Grzemska (WHO)
b) TB Infection Control
Chair: Gunta Dravniece (Latvia)
Facilitator: Bess Miller (US CDC)
Rapporteur: Rose Pray (WHO)

14:00 - 15:00  SALKHINO  PLENARY
Participation of stakeholders in TB control: past, present, future
Chair: Christine Lowery (UNICEF)
What is new in international TB control?
Paul Jensen (US CDC)
The WHO guidelines: what’s the way forward? Bess Miller (US CDC)

15:00 - 16:00  LILE  SIMULTANEOUS BREAK-OUT SESSIONS
a) Scaling-up patient and community participation in the Response to MDR/XDR.
Chair: Khaled Abu Ramman (Jordan)
Plenary presentations: Maxime Lunga (DR Congo) and Natalie Tarenec; Mamel Quelapio (Philippines)
b) TB Infection Control
Chair: Gunta Dravniece (Latvia)
Facilitator: Bess Miller (US CDC)
Rapporteur: Rose Pray (WHO)
PLENARY

Lilly MDR-TB partnership: Supporting the development of capacity building for TB control

Chair: Thelma Tupasi (Chair of the WG on MDR-TB)
Plenary presentations: World Medical Association, International Council of Nurses, International Federation of Red Cross Societies, International Hospital Federation, Partners in Health, WHO

LUNCH

Session 2
Translating best country practices into effective MDR-TB and XDR-TB response

PLENARY

Chair: Hamid Salim (Damian Foundation)

13:20-13:50
Update on Drug Resistance Surveillance
Abigail Wright (WHO)

13:50-14:20
The updated WHO guidelines on the programmatic management of drug-resistant TB
Karin Weyer (Chair of the Green Light Committee)

14:20-14:50
MDR-TB under the media spotlight
Glenn Thomas (WHO)

COFFEE BREAK

PLENARY

Progress reports from the Subgroups of the WGs:
Chair: Thelma Tupasi (Chair of the WG MDR-TB)

15:10-15:40
Green Light Committee
Karin Weyer (Chair of the GLC)
Friday, 21 September

Session 2
Ongoing efforts in treatment and control of MDR-TB: what's next?

9:00-10:20 SALKHINO PLENARY
Research on DR-TB
Frank Cobelens (Chair of the sub-group on MDR-TB research, of the MDR-TB WG)

10:50-11:30
Management of second-line anti-TB drugs
Robert Matiru (Manager of the GDF, Secretariat for the sub-group on drug management of the MDR-TB WG)

11:30-12:10
Laboratory Strengthening,
John Ridderhof (Chair of the subgroup on laboratory strengthening of the DOTS Expansion WG)

12:10-16:10
LUNCH

16:10-16:30
Management of second-line anti-TB drugs (continued)
Robert Matiru (Manager of the GDF, Secretariat for the sub-group on drug management of the MDR-TB WG)

16:30-16:50
Laboratory Strengthening (continued)
John Ridderhof (Chair of the subgroup on laboratory strengthening of the DOTS Expansion WG)

16:50-17:10
Advocacy and social mobilization on MDR-TB,
Nicole Schiegg (STP Secretariat for the advocacy and social mobilization WG)

17:10-17:30
TB Infection control
Bess Miller (Chair of the subgroup on infection control of the TB-HIV WG)

Saturday, 22 September

Session 3
Implementing the Global Response Plan to MDR-TB: what's next?

9:00-10:20 SALKHINO PLENARY
Reports of the break-out sessions and plenary discussion
Chair: Wang Xie Xiu (China)

9:00-9:40
Drug management

9:40-10:20
TB laboratory capacity

10:20-10:50
COFFEE BREAK

10:50-12:10 SALKHINO PLENARY
Reports of the break-out sessions and plenary discussion (continued)
Chair: Frank Cobelens (KNCV)

10:50-11:30
Community-based care and participation
PLENARY
11:30-12:10
Recording and reporting

12:10-13:00
LUNCH

13:00-14:20
SALKHINO
PLENARY
Reports of the break-out sessions and plenary discussion (continued)
Chair: Michael Kimerling (US)

13:00-13:40
Infection control

13:40-14:20
Scaling up country-wide and globally

14:20-15:00
SALKHINO
PLENARY
Thelma Tupasi (Chair of the MDR-TB WG)
WG governance issues: New composition of the Core Group, election of a new chair and vice-chair

Closing remarks